Biotechnology company and drug delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) today announced that Health Canada has issued cannabis Research and Development (“R&D”) license LIC-7NONT76UNW-2019 to its subsidiary, Lexaria CanPharm ULC. According to the update, the license, which carries a four-year term unless renewed, is effective immediately and will allow one of the country’s newest and most advanced formulation laboratories to conduct extensive investigatory work in THC and CBD delivery using optimized, proprietary formulations and techniques. The purpose-built laboratory is permitted at local and federal levels and fully outfitted to produce DehydraTECH(TM) infusions and includes two different methodologies by which the company can create nano-sized molecules when deemed beneficial. “Receipt of our R&D License from Health Canada will allow us to implement and complete investigatory studies significantly more rapidly now, than at any previous time in our Company’s history,” Lexaria President and Chief Scientist John Docherty said in the news release. “This license will greatly enhance our ability to work with cannabis Licensed Producers to perform work in-house on customized formulations that could benefit each of Canada’s licensed cannabis companies.”
To view the full press releases, visit http://ibn.fm/f8X80
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECH(TM) delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.